Ratio Therapeutics raised $70 million in a Series C round aimed at advancing radiopharmaceutical trials, including further work to support clinical development timelines. The company said the financing includes both existing investors such as Duquesne Family Office and Bristol Myers Squibb and new backers. The round underscores how radiopharma is continuing to attract capital for capacity-heavy programs where trial execution, manufacturing scale-up, and in-house analytical testing can drive burn rates quickly. For the sector, the deal signals continued investor appetite for targeted imaging and therapeutic radionuclide modalities.